Koers aTyr Pharma Inc Nasdaq
Aandelen
US0021201035
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 305K 279K | Omzet 2025 * | 7,46 mln. 6,82 mln. | Marktkapitalisatie | 117 mln. 107 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -64 mln. -58,54 mln. | Nettowinst (verlies) 2025 * | -58 mln. -53,05 mln. | EV/omzet 2024 * | 383 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 15,6 x |
K/w-verhouding 2024 * |
-1,81
x | K/w-verhouding 2025 * |
-2,26
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,37% |
Recentste transcriptie over aTyr Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30-07-18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08-09-05 |
Tim Coughlin
CHM | Chairman | 57 | 10-04-17 |
John Clarke
BRD | Director/Board Member | 70 | 01-09-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,74% | 47,54 mld. | |
-0,47% | 41,96 mld. | |
+43,96% | 41,55 mld. | |
+25,40% | 30,36 mld. | |
+17,96% | 27,61 mld. | |
-4,47% | 28,7 mld. | |
+50,73% | 14,7 mld. | |
+42,56% | 13,51 mld. | |
+1,46% | 12,34 mld. |